Dr. Christopher M. Reynolds, MD
Claim this profileSaint Joseph Mercy Hospital
Expert in Lung Cancer
Expert in Non-Small Cell Lung Cancer
51 reported clinical trials
104 drugs studied
About Christopher M. Reynolds, MD
Education:
- Obtained MD from Wayne State University School of Medicine in 2015.
- Completed Residency in Internal Medicine at St. Joseph Mercy Health System, serving as Chief Resident (2018-2019).
- Fellowship in Hematology/Oncology at the University of Michigan Rogel Cancer Center (2019-2022).
Experience:
- Currently practices as a Hematologist/Oncologist at Saint Joseph Mercy Hospital.
Area of expertise
1Lung Cancer
Global LeaderStage III
Stage IV
Stage II
2Non-Small Cell Lung Cancer
Global LeaderStage III
Stage IV
Stage II
Affiliated Hospitals
Clinical Trials Christopher M. Reynolds, MD is currently running
Chemotherapy + Immunotherapy
for Esophageal and Gastric Cancer
This phase III trial compares the effect of modified fluorouracil, leucovorin calcium, oxaliplatin, and irinotecan (mFOLFIRINOX) to modified fluorouracil, leucovorin calcium, and oxaliplatin (mFOLFOX) for the treatment of advanced, unresectable, or metastatic HER2 negative esophageal, gastroesophageal junction, and gastric adenocarcinoma. The usual approach for patients is treatment with FOLFOX chemotherapy. Chemotherapy drugs work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Fluorouracil stops cells from making DNA and it may kill tumor cells. Leucovorin is used with fluorouracil to enhance the effects of the drug. Oxaliplatin works by killing, stopping, or slowing the growth of tumor cells. Some patients also receive an immunotherapy drug, nivolumab, in addition to FOLFOX chemotherapy. Immunotherapy may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Irinotecan blocks certain enzymes needed for cell division and DNA repair, and it may kill tumor cells. Adding irinotecan to the FOLFOX regimen could shrink the cancer and extend the life of patients with advanced gastroesophageal cancers.
Recruiting2 awards Phase 32 criteria
Radium-223 + Cabozantinib
for Kidney Cancer with Bone Metastasis
This phase II trial studies whether adding radium-223 dichloride to the usual treatment, cabozantinib, improves outcomes in patients with renal cell cancer that has spread to the bone. Radioactive drugs such as radium-223 dichloride may directly target radiation to cancer cells and minimize harm to normal cells. Cabozantinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving radium-223 dichloride and cabozantinib may help lessen the pain and symptoms from renal cell cancer that has spread to the bone, compared to cabozantinib alone.
Recruiting1 award Phase 216 criteria
More about Christopher M. Reynolds, MD
Clinical Trial Related2 years of experience running clinical trials · Led 51 trials as a Principal Investigator · 25 Active Clinical TrialsTreatments Christopher M. Reynolds, MD has experience with
- Paclitaxel
- Carboplatin
- Nivolumab
- Pembrolizumab
- Cyclophosphamide
- Ipilimumab
Breakdown of trials Christopher M. Reynolds, MD has run
Lung Cancer
Non-Small Cell Lung Cancer
Breast Cancer
Breast cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Christopher M. Reynolds, MD specialize in?
Christopher M. Reynolds, MD focuses on Lung Cancer and Non-Small Cell Lung Cancer. In particular, much of their work with Lung Cancer has involved Stage III patients, or patients who are Stage IV.
Is Christopher M. Reynolds, MD currently recruiting for clinical trials?
Yes, Christopher M. Reynolds, MD is currently recruiting for 25 clinical trials in Ann Arbor Michigan. If you're interested in participating, you should apply.
Are there any treatments that Christopher M. Reynolds, MD has studied deeply?
Yes, Christopher M. Reynolds, MD has studied treatments such as Paclitaxel, Carboplatin, Nivolumab.
What is the best way to schedule an appointment with Christopher M. Reynolds, MD?
Apply for one of the trials that Christopher M. Reynolds, MD is conducting.
What is the office address of Christopher M. Reynolds, MD?
The office of Christopher M. Reynolds, MD is located at: Saint Joseph Mercy Hospital, Ann Arbor, Michigan 48106 United States. This is the address for their practice at the Saint Joseph Mercy Hospital.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.